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Glioblastomas (GB) are brain tumours with poor prognosis even after aggressive therapy. 
Improvements in both therapeutic and follow-up strategies are urgently needed. In previous work 
we described an oscillatory pattern of response to Temozolomide (TMZ) using a standard 
administration protocol, detected through MRSI-based machine learning approaches.  In the 
present work, we have introduced the Immune-Enhancing Metronomic Schedule (IMS) with an 
every 6-days TMZ administration at 60mg/kg, and investigated the consistence of such oscillatory 
behaviour.  
A total of n=17 GL261 GB tumour-bearing C57BL/6j mice were studied with MRI/MRSI every 2 days, 
and the oscillatory behaviour (6.2±1.5 days period from the TMZ administration day) was 
confirmed during response. Furthermore, IMS-TMZ produced significant improvement in mice 
survival (22.5±3.0 days for controls vs 135.8±78.2 for TMZ-treated), outperforming standard TMZ 
treatment. 
Histopathological correlation was investigated in selected tumour samples (n=6) analyzing control 
and responding fields. Significant differences were found for CD3+ cells (lymphocytes, 3.3±2.5 vs 
4.8±2.9 respectively) and Iba-1 immunostained area (microglia/macrophages, 16.8±9.7% and 
21.9±11.4% respectively).  
Unexpectedly, during IMS-TMZ treatment, tumours from some mice (n=6) fully regressed and 
remained undetectable without further treatment for one month. These animals were considered 
“cured” and a GL261 re-challenge experiment performed, with no tumour reappearance in 5 out 
of 6 cases.  
Heterogeneous therapy response outcomes were detected in tumour-bearing mice, and a selected 
group was investigated (n=3 non-responders, n=6 relapsing tumours, n=3 controls). PD-L1 content 
was found ca. 3-fold increased in the relapsing group when comparing with control and non-
responding groups, suggesting that increased lymphocyte inhibition could be associated to IMS-
TMZ failure. Overall, data suggest that host immune response has a relevant paper in therapy 
response/escape in GL261 tumours under IMS-TMZ therapy. This is associated to changes in the 
metabolomics pattern, oscillating every 6 days, in agreement with immune cycle length, which is 
being sampled by MRSI-derived nosological images.  
KEY WORDS: glioma; orthotopic tumours; immune response; metronomic therapy; immune 
memory, TMZ; PD-L1 
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1 | INTRODUCTION  
Glioblastoma (GB) is the most frequent type of primary central nervous system 
malignancy in adults with very poor prognosis, which has not significantly improved 
despite the development of new diagnostic strategies and innovative therapies.1 
Combination chemotherapy after surgery such as Temozolomide (TMZ) with 
radiotherapy have been used as standard adjuvant therapeutic choice producing an 
average survival of 14.6 months.2 
For therapy response assessment in GB, the most common monitoring approach is 
magnetic resonance imaging (MRI), which is the preferred modality to provide 
information about tumour size and local tumour tissue extension.3 Radiological and 
clinical guidelines are used to evaluate GB response to therapy, particularly through 
the application of the response assessment in neuro-oncology (RANO)4 and Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria.5 However, MRI information has 
been shown to be inaccurate due to the pseudoresponse and pseudoprogression 
phenomena occurring in some cases.6 Functional and molecular imaging can provide 
more accurate information and has attracted a lot of attention in the last decade. 
Among functional methods, magnetic resonance spectroscopy (MRS) may provide 
information about the metabolomic profile of the investigated lesion.7,8 Compared to 
MRS merely acquiring a single spectrum from a certain volume, magnetic resonance 
spectroscopic imaging (MRSI) is a technique that can provide metabolomic 
information superimposed to anatomical information, making it possible to gather this 




might be an interesting approach to complement MRI information in evaluating 
tumour response to therapy. 
Furthermore, the MRSI signal obtained from different types of tissue can be 
automatically categorized by pattern recognition (PR) techniques creating nosological 
maps potentially useful to detect and characterize therapy response in a noninvasive 
way.11–13 In this respect, the tumour responding index (TRI) as an evaluation 
parameter has been put forward to measure the extent of response to treatment 
using the obtained nosological images.14 In previous studies from our group, the multi-
slice MRSI technique has allowed us to observe TRI oscillations (ca. 6 days period) in 
GL261-tumour bearing mice treated with TMZ.14 Moreover, other authors have 
described that treatment with alkylating agents (e.g., TMZ) trigger the host immune 
system recruitment, eventually leading to tumour cell death. 15 Still, it has been 
described that the whole immune cycle in mice brain usually requires around six 
days16, which agrees with the oscillation period found in previous studies.14 Beyond 
that, it was described that administering chemotherapy with consecutive cycles every 
6 days could trigger immune system activation17 and we coined the expression 
“Immune-Enhancing Metronomic Schedule” (IMS) for this type of administration 
protocol18. In the late steps of each immune cycle, activated T cells traffic to and 
infiltrate the tumour bed, specifically recognizing and binding cancer cells and killing 
their target.19 In addition, microglial and macrophage cells, which can contribute up 
to 30% of a brain tumour mass, play a role in GB growth control.20 
Programmed death-1 (PD-1) and its ligand (PD-L1) play a key role in tumour immune 
escape and the modulation of tumour microenvironment, closely related with tumour 
generation and development.21 Chemotherapy can modify this tumour 
microenvironment. Thus, a recent study on 30 patients with thymic epithelial tumours 
revealed that PD-L1 expression increased in patient’s tumours after chemotherapy.22 
Similar findings have been communicated in other types of tumour such as rectal 
adenocarcinoma and breast cancer.23,24 These studies reveal a potential link between 
chemotherapy and tumour immunoresistance. However, little is known about how 
PD-L1 content changes in GB after chemotherapy, neither preclinical nor clinical.  
Consequently, in this work, our goal was to observe the evolution of TRI in GL261 
tumour-bearing mice treated with IMS-TMZ which was expected to enhance immune 
system participation in response to therapy. Furthermore, the tumour-associated 
immune population was characterized by histopathology studies, the contribution of 




term antitumour immune memory was examined by re-challenging TMZ-cured mice 
with GL261 glioma cells.  
2 | MATERIALS AND METHODS 
2.1 | GL261 cells  
GL261 mouse glioma cells were obtained from the Tumour Bank Repository at the 
National Cancer Institute (Frederick, MD, USA) and were grown as previously 
described.25 Cells were checked for mouse STR profile and interspecies contamination, 
as well as PCR evaluation to discard Mycoplasma and virus contamination. 
2.2 | Animal model  
All studies were approved by the local ethics committee (Comissió d’Ètica en 
Experimentació Animal i Humana (CEEAH, https://www.uab.cat/web/experimentacio-
amb-animals/presentacio-1345713724929.html ), according to the regional and state 
legislation (protocol CEA-OH-9685 / CEEAH-3665). 
A total of 37 C57BL/6 female wild-type (wt) mice weighing 22.4±2.2 g were used in 
this study. Six out of 37 C57BL/6 GL261 tumour bearing mice were generated in a 
previous study14 and further analyzed by histopathology studies in the present work. 
Thirty-one C57BL/6 GL261 tumour bearing additional mice were generated for this 
work (See Figure 1 and Table 1). They were obtained from Charles River Laboratories 
(l'Abresle, France) and housed in the animal facility of the Universitat Autònoma de 
Barcelona. Tumours were induced in C57BL/6 mice by intracranial stereotactic 
injection of 105 GL261 cells as previously described by us.26 Mice were weighed every 
other day and tumour volumes were followed twice a week using T2 weighted image 
(T2w) MRI acquisitions. Mice with the most homogeneous weights and tumour sizes 
were randomly chosen before therapy start to make experimental groups. 
 
2.3 | Animal treatment 
For in vivo experiments, TMZ (Sigma-Aldrich, Madrid, Spain) was dissolved in 10% 
dimethyl sulfoxide (DMSO) in saline solution (0.9% NaCl). IMS-TMZ 60 mg/kg was 
administered to n=19 tumour-bearing mice using an oral gavage, every 6 days, from 
day 11 post inoculation (p.i.), while control mice received 10% DMSO vehicle. After 
treatment, animals meeting endpoint criteria were euthanized by cervical dislocation 
according to animal welfare protocol advice for ethical reasons, the brain was removed 
and tumour resected. Animals cured by the IMS-TMZ therapy were followed up and a 
re-challenge experiment was carried out (see section 2.4 for further details). 




and two controls from 14. For these cases the TMZ administration scheme was the one 
described in previous studies, shown in Figure S1A. Still, control animals from 14 did 
not receive 10% DMSO vehicle.  
 
2.4 | Tumour-specific Immune memory studies  
2.4.1 |Criteria for cured mice 
When GL261 tumours were reduced after IMS-TMZ treatment until abnormal mass 
detection by MRI was no longer possible, or its volume remained stable (usually below 
2 mm3) during at least 2 weeks, TMZ administration was halted. Then, MR images were 
acquired twice a week. Whenever the volume of the residual/abnormal mass was 
stable or decreased for one month, mice were transiently declared "cured" as in17. 
2.4.2 |Re-challenge experiment 
Mice cured by the IMS-TMZ treatment (n=8) were inoculated with GL261 cells again, 
symmetric but contralateral to the initial injection site. For re-implantation, three 
C57BL/6 female wt mice were also implanted as controls, to check for consistency and 
growth rate in contralateral side. All mice were followed-up (weight + welfare 
parameters) twice a week and volumetric T2w MRI was acquired once a week. 
 
2.5 | In vivo MRI and MRSI studies  
2.5.1 | Data acquisition 
In vivo MRI/MRSI studies were performed at the joint nuclear magnetic resonance 
facility of the Universitat Autònoma de Barcelona and Centro de Investigación 
Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) 
(Cerdanyola del Vallès, Spain), Unit 25 of NANBIOSIS (www.nanbiosis.es). The 7T 
Bruker BioSpec 70/30 USR spectrometer (Bruker BioSpin GmbH, Ettlingen, Germany) 
equipped with a mini-imaging gradient set (400 mT/m) was used. A 72 mm inner 
diameter linear volume coil was used as transmitter, and a mouse brain surface coil as 
a receiver for brain MRI studies.  
Mice were positioned in a bed, which allowed delivery of anaesthesia (isoflurane, 1.5-
2.0% in O2 at 1 L/min), with an integrated heating water circuit for body temperature 
regulation. Respiratory frequency was monitored with a pressure probe and kept 
between 60–80 breaths/min. 
MRI studies 
GL261 tumour-bearing mice were screened by acquiring high resolution coronal T2w 




detect brain tumour presence and to monitor its evolution stage with repetition time 
(TR)/effective echo time (TEeff) = 4200/36 ms. The whole set of parameters used in 
MRI acquisitions can be found in the supplementary file. MRI data were acquired and 
processed on a Linux computer using ParaVision 5.1 software (Bruker BioSpin GmbH, 
Ettlingen, Germany). 
MRSI studies 
The MRSI acquisitions were performed every two days with mice in the longitudinal 
group, starting at day 15-17 post-implantation. 
Consecutive 14 ms echo time (TE) MRSI with point-resolved spectroscopy (PRESS) 
localization grids were acquired individually across the tumour, using as a reference 
T2w high resolution images, as described in previous work.14 Tumour was covered by 
3-4 MRSI grids with matrix size of 10x10 or 12x12 (technical details of MRSI 
acquisitions can be found in the supplementary file). In order to ensure quality of the 
acquired data, shimming was performed individually for each MRSI grid. MRSI grids 
were spatially located such that the volume of interest (VOI) included most of the 
tumoural mass as well as normal/peritumoural brain parenchyma. 
Water suppression was performed with Variable Power and Optimized Relaxation 
Delay (VAPOR), using a 300 Hz bandwidth. Linear and second order shims were 
automatically adjusted with Fast Automatic Shimming Technique by Mapping Along 
Projections (FASTMAP) and six saturation slices (ST, 10 mm; sech-shaped pulses: 1.0 
ms/20250 Hz) were positioned around the VOI to minimize outer volume 
contamination in the signals obtained.  
 
2.5.2 | MRI and MRSI Processing and Post Processing 
Tumour volume calculation 
Manual segmentation of abnormal brain mass in T2w images was performed and 
tumour volumes were calculated from T2w high resolution horizontal images using the 
equation:  
TV (mm3) = [(AS1 × ST) + [(AS2 + (. . .) + AS10) × (ST + IT)]] × 0.0752      (Equation 1) 
Where TV is the tumour volume, AS is the number of pixels contained in the region of 
interest in each slice of the MRI sequence, ST is the slice thickness, IT the inter-slice 
thickness and 0.0752 the individual pixel surface area in mm2. The tumour area was 
calculated from pixels in each slice with ParaVision 5.1 software. The inter-slice volume 
was estimated adding the inter-slice thickness to the corresponding slice thickness in 




Brain MRSI post‐processing and pattern recognition strategies 
MRSI data were post-processed essentially as described in.25 Briefly, data were initially 
pre-processed at the MR workstation with ParaVision 5.1, and then post-processed 
with 3D Interactive Chemical Shift Imaging (3DiCSI) software package version 1.9.17 
(Courtesy of Truman Brown, Ph.D., Columbia University, New York, NY, USA) for line 
broadening adjustment (Lorentzian filter, 4 Hz), zero-order phase correction and 
exporting the data in ASCII format. Dynamic MRSI processing Module (DMPM), 
running over MatLab 2013a (The MathWorks Inc., Natick, MA, USA) was used to align 
all spectra within each MRSI matrix, using the choline signal as reference, 3.21 ppm). 
The 0–4.5 ppm region of each spectrum in the MRSI matrix was normalized to unit 
length and exported in ASCII format for performing the PR analysis. No baseline 
correction was performed in these spectra.  
After that, the non-negative matrix factorization (NMF) semi-supervised methodology 
27,28 was applied for the extraction of meaningful source signals from the MRSI 
investigated tumours. From the biochemical viewpoint, the source extraction 
technique to classify MRS data assumes that in each voxel there is a mixture of 
heterogeneous tissues and their metabolites from which the contribution of each 
source can be obtained. A previously described semi-supervised approach29, which 
relies on Convex-NMF for the final source extraction, was used for classifying pixels 
into normal brain parenchyma, actively proliferating tumour and tumour responding 
to treatment; and for calculating nosologic maps representing the spatial response to 
treatment. Green colour is used when the GB responding to treatment source 
contributes the most, blue for normal brain parenchyma, red for actively proliferating 
GB and black for undetermined tissue. A more detailed explanation on NMF can be 
found in the Supplementary file.  
2.5.3 |Tumour Responding Index (TRI) calculations 
In order to measure the extent of response to treatment using the obtained 
nosological images, a numerical parameter named TRI was calculated (Equation 2) 14. 
             TRI =
Tumour responding pixels
 Total tumour pixels
× 100               (Equation 2) 
TRI is stated as the percentage of green, responding tumour pixels of all grids over the 
total tumour pixels of all recorded grids. Then, tentative ranges of TRI categories were 
established to classify the different response to treatment levels observed in the 
studied animals, taking into account both TRI percentage and volumetric data from 
MRI measurements according to RECIST criteria5. An adapted set of RECIST criteria was 
used to classify cases into Progressive disease (PD), Partial response (PRe) or Stable 




In this work, a TRI cycle was defined provided a change between maximum and 
minimum TRI values was above 10%. Values below this threshold were attributed to 
possible experimental variability and were not counted as ‘cycles’. 
2.6 | Antibodies 
For histopathology studies, Anti-CD3 antibody (dil. 1:300, rabbit, Ref A0452) was 
purchased from Dako (Santa Clara, CA, USA) and Anti-Iba-1 antibody (dil. 1:300, goat, 
Ref ab5076) was purchased from Abcam (Cambridge, UK). 
For PD-L1 WB studies, Anti-PD-L1 antibody (dil. 1:400, rabbit, Ref ab233482) was 
purchased from Abcam (Cambridge, UK), β-tubulin antibody (dil. 1:1000, rabbit, Ref 
2146) was purchased from Cell Signalling Technology (Beverly, MA, USA) and 
secondary antibody towards rabbit IgG (dil.1:2000), conjugated to horseradish 
peroxidase, was purchased from Bio-Rad (Richmond, CA, USA). 
2.7 | Histopathology studies  
TMZ-treated cases used for histopathological validation were the following: C1100 (TRI 
= 61.8%), C1108 (TRI = 70.3%), C971 (TRI = 44.1%) and C1022 (TRI = 46.5%). In addition, 
two control (non-treated) tumour-bearing mice were also explored (C1110 and C1111). 
MRI/MRSI data, nosological images and TRI calculations are described in.14 
Fixed brains were embedded in paraffin and serial horizontal sections were cut, taking 
into account MRSI slices in order to ensure spatial correlation. Brain was split in half 
and each half was cut in 20 sections of 5 µm. The upper half of the brain corresponded 
to MRSI Grids 1 and 2, while the lower half of the brain corresponded to MRSI Grids 3 
and 4. 
One section corresponding to each MRSI Grid position was selected for CD3+ 
immunohistochemical staining for detecting the presence of T lymphocytes and Iba-1 
immunohistochemical staining for detecting the presence of activated 
macrophages/microglia in treated and control tumours. 
After immunostaining, the preparations were digitized for quantification using a 
Nanozoomer 2.0HT (Hamamatsu Photonics France, Massy, France). Then, CD3+ 
positive cells and percentage of Iba-1 positive immunostained cellular areas were 
counted in each section in fields that corresponded to green or red tumour areas in 
nosological images. From each chosen area, 5 fields of 0.025 mm2 were randomly 
selected at 40x magnification, using NDPview 1.2.53 software (Hamamatsu Photonics 
France SARL, Massy, France). Fields were placed in the more highly cellular areas, 
avoiding poor or acellular areas. Exceptionally, in some samples, fewer fields were 




evaluate 5 fields. 
 
 
2.8 | PD-L1 expression by Western blotting  
Cases used for PD-L1 expression were those with the following codes: fast growth 
tumours escaping IMS-TMZ therapy right from the start, defined as “non-responding” 
(C1288, C1319 and C1356, n=3); cases showing transient tumour shrinkage but 
eventually relapsing, defined as “relapsing” (C1290, C1292, C1341, C1342, C1343 and 
C1349, n=6). Control cases received 10% DMSO vehicle with the same schedule (C1266, 
C1300 and C1317, n=3).   
Tissue Homogenization and Protein Extraction. Whole GL261 tumours obtained after 
euthanization at endpoint were weighted and protein extracted as described in 30, 
details can be found in Supplementary file. Protein concentration was determined by 
Bradford assay (Bio-Rad) and equal amounts of protein (80 µg) were loaded on 12% 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), blotted on 
polyvinylidene fluoride (PVDF) Immobilon-P membranes (Millipore, Darmstadt, 
Germany), and immunodetected with the corresponding antibodies using a 
chemiluminescent detection method (ClarityTM Western ECL Blotting Substrates, Bio-
Rad, California, U.S.A.). Chemiluminescent signal was obtained with Chemidoc MP 
Image System and quantified with the ImageJ software. 
 
2.9 | Statistical analysis  
Variance homogeneity was assessed with the Levene’s test. Sample distribution was 
assessed with the Kolmogorov-Smirnov test. A two-tailed Student’s t-test for 
independent measurements was used for comparisons, for samples of equal or 
different variances (depending on the Levene’s test result). Comparisons of survival 
rates were performed with the Log-Rank test. The significance level for all tests was 
p<0.05.  
3 | RESULTS  
Table 1 summarizes the cases described in this study and the analyses performed with 
each one. 
3.1 | IMS-TMZ treatment and follow up in GL261 tumour-bearing mice  
In this part of the study 19 mice were used. Among them, 13 mice were treated with 
TMZ using an IMS protocol and 6 were administered with vehicle, also in an IMS 




be found in Figure S1A. All mice were followed-up according to the supervision 
parameters for animal health status and weighted (Figure S1C). The tumour volume at 
therapy starting (day 11 p.i.) in this section was 5.4 ± 2.6 mm3, close to tumour volumes 
in previous work with similar TMZ schedule (6.0± 1.2 mm3)30. Tumour volume 
evolution of vehicle and TMZ-treated mice is shown in Figure S1B. As described 
before,31 TMZ treatment with the IMS administration has a positive impact in the 
survival of GL261 tumour-bearing mice (Figure S1D). Thus, the average survival rate 
for control mice was 22.5 ± 3.0 days whereas the TMZ-treated animals survived 
significantly more, 135.8 ± 78.2 days (p<0.05 according to Log Rank Test), being 61.5% 
of TMZ treated mice alive at day 150 p.i. and some individuals still alive at 464 days p.i.  
 
3.2 | Multi-slice MRSI-based volumetric analysis of therapy response assessment under 
IMS-TMZ treatment  
A longitudinal study was performed with eleven TMZ-treated GL261 tumour-bearing 
mice and six vehicle treated mice (see Table 1 for individual codes). Mice were studied 
every two days (see Figure S2A) until endpoint. The start of MRSI explorations was 
conditioned by the measured tumour volume. According to our experience and data 
described by our group31, tumour volumes below 10-20 mm3 are not properly 
segmented by MRSI, and this was the cut-off point to start MRSI acquisitions. An 
example can be seen in Figure S2B. Results are summarized below. 
 
3.2.1| TMZ-treated mice  
The relationship between TRI and tumour volume evolution, as well as the 
corresponding nosological images of three most representative cases of TMZ treated 
mice are shown in Figure 2 (for the remaining cases, refer to Figures S3 and S4).  
Several TRI oscillations were observed in the TMZ-treated mice and these were 
generally coincident with SDi and PRe tumour stages (Table S1), according to the 
adapted RECIST criteria. Oscillations were observed between days 17 and 39 p.i. 
depending on the case observed. It is worth mentioning that in the first MRSI time 
points (days 15-19 depending on the case), where the evolution tumour would be still 
classified as PD, TRI oscillations can already be seen.  
In five cases (C1263, C1264, C1270, C1380 and C1383) tumour escaped from therapy 
and met PD criteria, leading to the euthanization of the mice. During this relapse, 
which started between days 35-41, either TRI cycles were not found anymore, or this 
value was no longer reliable. When the slope of the tumour growth increased 
dramatically or tumour relapsed beyond volumes of ca. 50 mm3, TRI do not seem to 




high tumour volume (>70mm3) and relatively low TRI (e.g. C1270, TRI <40%) resulted 
in bad survival outcome in comparison with other cases, and tumour grew 
uncontrolled until the second TRI oscillation appearance.  
Regarding cases with complete follow-up, a total of 48 doses of TMZ were given, 
resulting in 26 TRI oscillation peaks, 21 of them corresponding with tumour growth 
arrest or volume decrease, whereas 5 TRI peaks were no longer able to coincide with 
controlled tumour growth (almost exclusively at relapsing time points). In addition, 8 
TMZ doses corresponded to periods in which tumour volume were below the 
minimum volume for nosological imaging segmentation while 2 TMZ doses 
corresponded to endpoint with no further explorations made.  
It is worth mentioning that TRI peak appear ca. 6-8 days after the first therapy 
administration period. The only case which delayed this appearance – 12 days, but 
only 6 days after the second therapy dose, C1383– could be due to segmentation 
problems due to borderline tumour volume between therapy cycles one and two. For 
all followed tumours, the first TRI peak agreed with a certain decrease in the tumour 
growth slope. 
Spectra acquired were of overall good quality and examples of chosen MRSI spectra 
for case C1263 are shown in Figure S2A. 
 
3.2.2| Additional cases from cured mice 
For mice with full MRI/MRSI follow-up, six of the TMZ treated mice analyzed (see Table 
1 for individual codes) had tumours which disappeared after IMS-TMZ treatment, 
which obviously prevents the generation of nosological images. Details about their 
tumour volume and TRI evolution can be found in the supplementary material (Figure 
S3).  
As in other TMZ-treated mice, TRI oscillations or punctual increases could be found for 
most cases. For example, in the first days of MRSI monitoring, TRI cycles were found in 
four out of six cases. After that time, the relationship between tumour volume 
evolution and TRI changes was different in every case.  
The maximum volume achieved in this group was 37.4 mm3, and tumour volume 
decrease was found around the second TMZ therapy dose, lasting until ca. day 30 p.i. 
For cases with enough volume for nosological imaging segmentation, oscillations were 
seen during active response. For example, case C1276 (Figure S3A) showed TRI 
oscillations from days 17 till 27 p.i., when the tumour was classified either as SDi or 
PRe. Case C1382 presented TRI oscillations at days 17 and 21 p.i., followed by a gradual 
decrease which concurred with tumour disappearance.  




4.3±1.4 mm3 vs 6.9±3.4 mm3 in non-cured mice from this work), although this 
difference was not statistically significant.   
 
3.2.3| Vehicle-treated mice 
Six vehicle-treated mice were analysed for comparison purposes (Figures S5 and S6). 
The tumour evolution in this group was classified as PD throughout the period of MRSI 
analysis (Table S2), as expected. The TRI oscillatory pattern is not observed in any of 
the cases, except in the C1258, where a possible TRI cycle is observed (Figure S5), 
although tumour growth slope did not decrease. In the remaining 5 cases, no TRI cycles 
were observed, indicating that clear TRI oscillations are only present when tumour-
bearing mice respond to IMS-TMZ treatment.  
 
3.3 | Histopahology validation  
Six mice were used for histopathological analysis, 4 treated with TMZ and two non-
treated. Comparison of responsive and unresponsive zones (i.e. green and red areas 
of the nosological images) was performed (see Figure 3). Responsive zones presented 
significantly higher CD3+ positive cell counting and higher percentage of Iba-1 
immunostained area in comparison with unresponsive zones. Values for CD3+ were 
4.8 ± 2.9 and 3.3 ± 2.5 CD3+ positive cells in responsive and unresponsive zones, 
respectively (n=53 and n=94 fields). For Iba-1, the percentage of positive 
immunostained area was 21.9 ± 11.4% for responsive and 16.8 ± 9.7% for unresponsive 
zones (n=53 and n=95 fields). Individual fields from responsive zones could achieve 
values up to 42% of area occupancy by Iba-1 positive cells while unresponsive zones 
could reach values as low as 1.4%. Although it could be contributing to the MRSI-
detected spectral pattern changes, there is variability, and differences between 
regions within the same tumour are not so clear cut in certain individual cases. 
 
3.4 | PD-L1 content in GL261 tumours  
PD-L1 content was analyzed in 12 frozen dissected GL261 tumours: 9 from IMS-TMZ 
treated mice and 3 control, with growth curves shown in Figure S7. WB results and 
quantification are shown in Figure 4. After normalization to Tubulin, PD-L1 band 
intensity was 0.23 ± 0.04 in the GL261 control group whereas it was 0.64 ± 0.14 in the 
relapsing GL261 group and 0.19 ± 0.02 in non-responding group. The PD-L1 content 
was found significantly higher (p<0.001) in the relapsing group when comparing with 
control group (2.8 fold) and non-responding group (3.4 fold), whereas no differences 




3.5 | IMS-TMZ activates Tumour-specific immune memory  
We were also interested in a preliminary evaluation of whether IMS-TMZ treatment 
could induce long-term antitumour immunity in the cured C57BL/6 mice (tumour 
growth curves shown in Figure S8). For that, the re-challenge experiment described in 
section 2.4.2 was performed. Three wt mice were implanted in parallel as controls. 
Control tumours grew normally and no significant differences were found with 
standard GL261 tumour doubling time of 2.4 ± 0.3 days32. Regarding the re-challenged 
mice, only one of re-implanted tumours in the TMZ-cured mice (case C1286) grew after 
10 days while the rest remained tumour-free until present time (range 150-464 days 
post-implantation). With respect to case C1286, TMZ was administered as usual in an 
IMS protocol and tumour disappeared after only one TMZ dose. After being cured 
again, this mouse has been followed-up (weight + welfare parameters) twice a week 
and MRI acquisitions were acquired once a week, for the rest of its lifetime (until 175 
days post-implantation) and no tumour mass has been detected in its brain. 
This high rate (100 %) of tumour rejection (Table 2) suggests that the cured mice seem 
to be acquiring antitumour immune memory to GL261.  
 
The tumour volume and TRI graph of a representative case (C1276) displaying immune 
memory is shown in Figure 5. For this specific case, tumour reached a maximum 
volume of 18.2 mm3 at day 17 p.i., decreasing to 1.5 mm3 after 7 TMZ doses. Two TRI 
cycles were observed during tumour-shrinking (Figure S4). The scar/residual abnormal 
mass caused by tumour growth was stable for one month; therefore, the mouse was 
declared as cured (see section 2.4.1). On day 74 p.i this cured mouse was re-implanted 
on the other side of the brain parenchyma with GL261 cells. No tumour mass was 
detected in the cured mouse brain within 3 months after tumour re-implantation 
 
4 | DISCUSSION 
4.1 | IMS-TMZ therapy triggering a repeated oscillatory TRI behavior  
During this work, eleven TMZ-treated and six vehicle treated tumour-bearing mice 
were analyzed by MRSI-based nosological images (representative cases shown in 
Figures 1, S3-S6). Results confirmed the oscillatory response level (i.e. TRI values) of 
TMZ-treated mice due to changes in the metabolomic spectral pattern. This was 
already shown in a previous study with the standard 5-2-2 TMZ administration 
protocol in a smaller cohort of animals 14 but its reproducibility with the IMS-TMZ 
protocol had not yet been tested. Multi-slice MRSI acquisitions allowed us not only to 




sample intratumour heterogeneity. The TMZ administration seems to be the 
responsible of “setting” cycles, since the period between therapy administration and 
appearance of a TRI peak is consistent along different cases, ranging 4-8 days during 
regular transient response periods. Also, it has been shown that, prior or during 
tumour relapse, these oscillations disappeared, with a different TRI behavior: it either 
assumed an increasing, non-oscillating trend or only showed small, incipient increases. 
This confirms that consistent TRI oscillations are related to metabolomic changes due 
to tumour response, but mostly absent during tumour relapse. The average value for 
time lapse recorded between TMZ administration and TRI peak appearance (being TRI 
peak average 66.8 ± 22.3 % in all studied cases, n = 11) was 6.2 ± 1.5 days.  
In control cases (Figures S5-S6), no TRI oscillations were observed, with the possible 
exception of case C1258, although no coherent tumour decrease was seen at possible 
TRI peak in C1258. This suggests that the lack of response to therapy leads to absence 
of clear TRI oscillation. In such cases, an increase in TRI could suggest local 
metabolomics changes resembling the ones observed during therapy (e.g. 
spontaneous host immune response), although these are clearly not enough to arrest 
tumour growth.  
Results from TMZ-treated mice suggest that TMZ administration “resets” the immune 
system cycle clock, since TRI maximum peaks appear in average 6.2 ± 1.5 days after 
therapy administration (Figures 1, S3 and S4). This value is in agreement with work 
previously published by us with a non-metronomic TMZ administration schedule 
(distance between TRI maxima, 6.3 ±1.3 days, n=4, 14) and also with calculations 
approached in single-slice acquired cases (distance between TRI maxima, 6.2 ± 2.0 
days, calculated for n=3 cases from 29). This value is also in line with the length of 
immune cycle in mice brain, described to be of ca. 6 days 33. Moreover, taking into 
account that TMZ has already been described to behave as an immunogenic drug, 
which triggers the exposure and release of immunogenic signals 34,35, we hypothesize 
that each TMZ cycle is triggering a new ‘turn’ of the immune cycle leading to an arrival 
of new sub-clones of immune system cells within tumours ca. 6 days later. This would 
contribute to metabolomic pattern changes sampled by MRSI acquisitions, leading to 
changes in nosological images (see figure 6 for a schematic explanation).  
Still, it is worth noting that TRI peak maxima are also accompanied, in some instances, 
by a reduction of the tumour volume characterizing either a partial response case (see 
Figure 2, case C1263 and C1270) or stable disease (case C1264). This reproducible 
behavior may underlie that a high TRI is indicating an active anti-tumoural response 
triggered by the immunogenic potential of TMZ. 
The monitoring of TRI evolution could enable the design of personalized therapeutic 




tumour effect. Once fully validated that the ‘green pattern’ is associated with a 
productive action of the host immune system against the tumour, its presence would 
indicate that no further TMZ doses are needed until TRI starts decreasing, which would 
mean that a new, resistant clone of tumour cells is replacing cells killed by immune 
system action. The new TMZ administration would trigger a new turn in the immune 
system cycle, with priming and amplification of lymphocytes enabling them to kill this 
new tumour cells sub-clone. 
One of the handicaps of the MRSI-based nosological image calculation technique is 
that small sized tumours do not produce confident segmentation (e.g. case C1263 in 
which the tumour zone was mislabeled as normal brain parenchyma, Figure S2B). We 
named this period “below threshold detection period” (BTDP) since the semi-
supervised source analysis software was not able to properly segment the tumour. 
However, since small tumours have a trend to better survival or either cure, the 
metabolomics signature would not be as relevant as in tumours with larger volumes, 
in which this information is relevant to assess the efficacy of a therapeutic strategy. 
These results demonstrate how non-invasive methods based on PR analysis of MRSI 
acquisition can be applied in order to improve therapeutic success, making it possible 
to develop enhanced and personalized therapies based on metabolomic information, 
which takes place before or in the absence of MRI volume-related changes. 
Finally, if the relationship between TRI cycles and efficient host immune system 
attraction for tumour fighting is fully confirmed, we should be also able to evaluate 
and quantify the response level in combined treatments (e.g. synergistic TMZ+ anti-
PD-1 or TMZ + CX-4945, an ATP-competitive CK2 protein kinase inhibitor described for 
preclinical GB treatment30), as well as to refine administration timing. Our surrogate 
biomarker for therapy response, coded in nosological images, was developed with 
TMZ-treated cases 29 and one of the fundamental questions then was whether it would 
be useful with other therapeutic agents. Indeed, it was also proven robust to detect 
tumour response in cyclophosphamide (CPA) treated mice31, suggesting that the 
changes sampled are not restricted to TMZ, but rather being related to local changes 
during different treatments. Those would be probably related to immune system 
action against tumours, which could be an extremely valuable biomarker in tuning 
therapy administration to obtain maximal effectiveness and improve outcome. 
4.2 | Histopathology results  
Our working hypothesis is that the recorded TRI oscillations could be at least partially 
due to local metabolic changes resulting from immune system action within the 
tumour tissue. This hypothesis is supported by histopathological findings (section 3.3 




presented a higher number of lymphocyte-like cells in comparison with untreated 
samples. This was further confirmed with immunostaining for CD3+ (T lymphocytes 
marker) and Iba-1 (microglia/macrophages marker). Values were significantly higher 
in tumour zones classified as “responding”, in comparison with control cases or 
“unresponsive” areas. Moreover, the TRI imaging biomarker was proven to be 
correlated with the proliferation index Ki67 14,29, also reflecting that metabolomics 
changes could be related to the proliferation status of tumour cells.  
Results obtained in the present work reinforce the concept of IMS-TMZ as a good 
alternative for GB treatment. This hypothesis needs to be further validated in future 
work by assessing the recruitment of the host immune system elements through 
histopathological validation during TRI maximum and minimum values: in addition to 
CD3 and Iba-1, other markers such as FoxP3 (regulatory T lymphocytes) or specific 
markers for different polarization extremes of macrophages (M1 and M2 subtypes) will 
be useful. Importantly, this may be of relevance due to the fact that 
macrophages/microglia intimately interact with tumour cells and may contribute, 
depending on the cellular subtype, to tumour growth, migration and invasion of 
tumour cell, destruction of the extracellular matrix, neoangiogenesis and an 
immunosuppressive microenvironment. 36 Also, their quantification at different time 
points along therapy protocols would be of help to understand better their potential 
contribution to the metabolomics pattern of responding and non- responding tumours.   
4.3 | A possible explanation for resistance to TMZ therapy in GL261 tumours: PD-L1 
content increase  
Immune evasion is one of the features of cancer37, and overexpression of PD-L1 on the 
surface of the cancer cells is one way of escaping the immune system attack.38 Several 
studies reveal that up-regulated expression of PD-L1 on tumour cells could be a 
potential link between chemotherapy and tumour immunoresistance 22–24. In some 
cases studied in this work, we observed a transient therapy response to IMS-TMZ 
followed by fast tumour regrowth. WB results shows that increased PD-L1 content was 
found in late relapsing tumours when comparing to vehicle-treated tumours, which 
could provide a possible explanation for relapse in these mice.  
In this respect, other authors have already described that treatment with alkylating 
agents (e.g., TMZ) trigger host immune system recruitment.15 Our hypothesis is that 
one of the reasons contributing to GL261 tumour regrowth during IMS-TMZ would be 
the appearance of tumour cell sub-clones which up-regulate PD-L1. These PD-L1 over 
expressing tumour cells would be protected from productive T-lymphocyte attack and, 
consequently, would replace the tumour cell population not overexpressing PD-L1. 




increased PD-L1 content. With respect to control tumours, they should barely trigger 
the production of immunogenic signals due to the lack of damage caused by TMZ, thus 
resulting in less T cell infiltration into tumour tissue. Accordingly, no selection of 
tumour cells with increased PD-L1 expression for clonal expansion would happen.  
In the case of “non-responding” GL261 tumours, results show that the expression level 
of PD-L1 is equivalent to vehicle-treated tumours, and lower than in late relapsing ones. 
Our hypothesis to explain this difference is that “non-responding” tumours would 
escape therapy by a different mechanism, not yet clarified, rather than “late relapsing” 
tumours, which could use high PD-L1 content for this. Initial tumour mass duplication 
time and, eventually, overall tumour mass could probably hamper on its own immune 
system capability of the host39, then, no positive selection for PD-L1 high expression 
clones would be required in this instance for tumours to grow unencumbered. This 
result brings us significant insight for future research in preclinical GL261 GB, indicating 
that anti- PD-1 immunotherapy should be more effective as second line treatment in 
late relapsing GL261 tumours, while combined TMZ and kinase inhibitors such as CX-
4945 may be best for fast growth, “non-responding” GL261 tumours. In addition, 
kinase inhibitors could contribute an added value through another pathway, impairing 
hypoxia-inducible factor (HIF) stabilization which in turn could lead to decrease of PD-
L1 content.40 These hypotheses are amenable to test in future work and can lead to 
further improvement of the outcome of tumour-bearing mice.  
4.4 | IMS-TMZ therapy may establish long-term specific anti-tumour immunity. 
Alkylating agents such as CPA and TMZ have been described to induce the 
immunogenic cell death of tumour cells by activating the immune system through the 
exposure and emission of damage-associated molecular patterns (DAMPs), triggering 
the recruitment of the host immune system 15,34,41,42 . However, as relevant as eliciting 
the immune system is avoiding to impair its amplification, and here the IMS gains 
importance. In the GL261 mouse model, TMZ produces a significantly better survival 
rate when administered in a 6-day cycle 30 instead of in daily schedule of 5 consecutive 
days 43. Alkylating agents, including TMZ, are known to induce side effects related to 
the immune system such as leukopenia and neutropenia, when administered daily 44. 
If TMZ is administered in a continuous schedule, the anti-tumour immune cycle may 
be hampered due to the inhibition of the proliferation of immune cells, such as primed 
CD8+ T lymphocytes. On the other hand, in a metronomic administration schedule, 
TMZ would not interfere with the proliferation of immune cells (time period in Figure 
6C), since the next TMZ dose is administered after completion of the amplification step. 
This would be of benefit to establishing long-term specific anti-tumour immunity. 




IMS-TMZ-cured mice resisted secondary re-challenge tumour development. Our 
preliminary findings in this suggest that antitumour immunological memory is 
established by the host immune system of cured mice. The efficiency to trigger 
antitumour immunity may be supported by the induction of immunogenic cell death 
by the TMZ effect on GL261 tumour cells18. In this respect, we cannot ignore that 
GL261 is a moderately immunogenic cell line45. Thus, a basal part of the response to 
therapies may be helped by this basal immunogenicity, like in “hot” tumours46. 
Nonetheless, it seems clear that this basal immunogenicity alone is not able to make 
C57BL/6 mice resistant to GL261 GB growth, in the absence of IMS-TMZ therapy 
(Figure S1B). Accordingly, this IMS-TMZ may promote long-term therapeutic responses 
through generation of immunological memory with concomitant prevention of 
tumour relapse. Wu and Waxman17 found an increased number of CD8+ T cells and 
decreased number of circulating macrophages and myeloid-derived suppressive cells 
(MDSCs) populations in cured mice treated with “metronomic” IMS-like CPA treatment, 
which rejected the GL261 tumour on re-challenge17. In this sense, further work will be 
needed to explore the actual mechanism of antitumour immune memory in our 
system; thus, assessment of different immune populations could be performed in mice 
that rejected the re-implanted GL261 tumours compared to control tumours. Animal 
models of cancer are used to produce results of relevance for translation to human 
patients, eventually. In this respect, one relevant corollary of the described work from 
the imaging part should be that MRS/MRSI studies of glioblastoma patients during 
treatment should consider whether oscillatory variations comparable to the ones 
described in this work for GL261 GB under therapy may be happening, and exercise 
due caution interpreting single datapoint results to predict response to therapeutic 
strategies being evaluated. 
In addition to the beneficial effects related to immune system, the IMS administration 
schedule also allows us to reduce the cumulative amount of administered TMZ and 
avoid consequent development of other tumours due to the mutagenic effects of TMZ, 
such as lymphomas31. Moreover, if a translational protocol reaches the clinical pipeline, 
the reduction of TMZ dosage should also decrease undesired side effects in patients. 
The curative effect of the IMS-TMZ protocol alone in 38% of the overall investigated 
mice, indicates that similar protocols, avoiding damage to the amplification phase of 
the immune cycle, could be of relevance to patients 
5 | CONCLUSIONS  
Results in this work confirmed that the IMS-TMZ protocol produced the expected 
oscillatory changes in the metabolomic pattern sampled by MRSI-based nosological 




host immune system onto the GL261 tumour during therapy monitoring, especially 
during transient response. TMZ administered using the Immune-Enhancing 
Metronomic Schedule produces significantly better survival rate than non-IMS 
protocols and may even establish long-term specific anti-tumour immunity in cured 
mice. With regard to GL261 GB tumours showing transient response to therapy 
followed by tumour regrowth, PD-L1 content increase in the tumour tissue could be a 
possible explanation for the recurrence. Further studies will be needed to assess the 
presence, type and amount of recruited host immune system elements at the point of 
maximum and minimum TRI values. This will help us to understand better their 
potential contributions to the metabolomic pattern changes detected. Finally, 
whenever the relationship between TRI oscillations and productive host immune 
system attraction for tumour fighting is fully demonstrated, we should be also able to 
use this to evaluate and quantify the extent of response in combination therapies, 
thereby further improving therapy scheduling and allowing for its personalization. 
 
ACKNOWLEDGEMENTS 
This work was funded by the Ministerio de Economía y Competitividad (MINECO) grant 
MOLIMAGLIO (SAF2014-52332-R) to CA. Also funded by Centro de Investigación 
Biomédica en Red – Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, 
[http://www.ciber-bbn.es/en], CB06/01/0010), an initiative of the Instituto de Salud 
Carlos III (Spain) co-funded by EU Fondo Europeo de Desarrollo Regional (FEDER). APC 
received funding from the ATTRACT project funded by the EC under Grant Agreement 
777222. We acknowledge the UAB Predoctoral training programme (14ª Convocatoria 
PIF-19612 and 13ª Convocatoria PIF, predoctoral fellowships for Ms P. Calero and L. 
Villamañan), Ministerio de Economia y Competitividad (FPI fellowship BES-2012-
055741 for Dr. N. Arias-Ramos) and also China Scholarship Council (predoctoral 




1.  Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10-14. 
2.  Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant 
temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III 
study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466. 
3.  Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET 
imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 
2010;9(9):906-920. 
4.  Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for 




Working Group. Neurosurgery. 2012;70(1):234-43; discussion 243-4. 
5.  Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. 
6.  Hygino da Cruz LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression 
and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma. Am J 
Neuroradiol. 2011;32(11):1978-1985. 
7.  Pichler BJ, Wehrl HF, Judenhofer MS. Latest Advances in Molecular Imaging Instrumentation. J 
Nucl Med. 2008;49(Suppl_2):5S-23S. 
8.  Horská A, Barker PB. Imaging of Brain Tumors: MR Spectroscopy and Metabolic Imaging. 
Neuroimaging Clin N Am. 2010;20(3):293-310. 
9.  Hattingen E, Jurcoane A, Bahr O, et al. Bevacizumab impairs oxidative energy metabolism and 
shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic 
resonance imaging study. Neuro Oncol. 2011;13(12):1349-1363. 
10.  Nelson SJ. Assessment of therapeutic response and treatment planning for brain tumors using 
metabolic and physiological MRI. NMR Biomed. 2011;24(6):734-749. 
11.  Ortega-Martorell S, Julià-Sapé M, Lisboa P, Arús C. Pattern Recognition Analysis of MR Spectra. 
In: EMagRes. Vol 5. Chichester, UK: John Wiley & Sons, Ltd; 2016:945-958. 
12.  Laudadio T, Martínez-Bisbal MC, Celda B, Van Huffel S. Fast nosological imaging using canonical 
correlation analysis of brain data obtained by two-dimensional turbo spectroscopic imaging. 
NMR Biomed. 2008;21(4):311-321. 
13.  Simões RV, Ortega-Martorell S, Delgado-Goñi T, et al. Improving the classification of brain 
tumors in mice with perturbation enhanced (PE)-MRSI. Integr Biol (Camb). 2012;4(2):183-91. 
14.  Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, et al. Metabolomics of Therapy Response in 
Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive 
Assessment of Temozolomide Treatment. Metabolites. 2017;7(2):20. 
15.  Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic Adenovirus With Temozolomide Induces 
Autophagy and Antitumor Immune Responses in Cancer Patients. Mol Ther. 2013;21(6):1212-
1223. 
16.  Karman J, Ling C, Sandor M, Fabry Z. Initiation of Immune Responses in Brain Is Promoted by 
Local Dendritic Cells. J Immunol. 2004;173(4):2353-2361. 
17.  Wu J, Waxman DJ. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by 
activating antitumor Cd8 + T-cell responses and immune memory. Oncoimmunology. 
2015;4(4):e1005521. 
18.  Villamañán L. Unraveling CK2 inhibition and temozolomide contribution to therapy response in 
preclinical GL261 glioblastoma: immune system implications and magnetic resonance based 
nosological imaging. PhD Thesis, Univ Autònoma Barcelona. January 2019. 
https://tdx.cat/handle/10803/666881. 
19.  Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 
2013;39(1):1-10. 
20.  Lorger M. Tumor Microenvironment in the Brain. Cancers (Basel). 2012;4(1):218-243. 
21.  He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune 
Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep. 2015;5(1):13110. 
22.  Katsuya Y, Horinouchi H, Asao T, et al. Expression of programmed death 1 (PD-1) and its ligand 




after chemotherapy. Lung Cancer. 2016;99:4-10. 
23.  Hecht M, Büttner-Herold M, Erlenbach-Wünsch K, et al. PD-L1 is upregulated by 
radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable 
prognosis. Eur J Cancer. 2016;65:52-60. 
24.  Zhang P, Su D-M, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 
(PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. 
Mol Immunol. 2008;45(5):1470-1476. 
25.  Simões RV, Delgado-Goñi T, Lope-Piedrafita S, Arús C. 1 H-MRSI pattern perturbation in a mouse 
glioma: the effects of acute hyperglycemia and moderate hypothermia. NMR Biomed. 
2010;23(1):23-33. 
26.  Simões R V, García-Martín ML, Cerdán S, Arús C. Perturbation of mouse glioma MRS pattern by 
induced acute hyperglycemia. NMR Biomed. 2008;21(3):251-264. 
27.  Ortega-Martorell S, Ruiz H, Vellido A, et al. A Novel Semi-Supervised Methodology for Extracting 
Tumor Type-Specific MRS Sources in Human Brain Data. Monleon D, ed. PLoS One. 
2013;8(12):e83773. 
28.  Ortega-Martorell S, Lisboa PJG, Vellido A, et al. Convex Non-Negative Matrix Factorization for 
Brain Tumor Delimitation from MRSI Data. Monleon D, ed. PLoS One. 2012;7(10):e47824. 
29.  Delgado-Goñi T, Ortega-Martorell S, Ciezka M, et al. MRSI-based molecular imaging of therapy 
response to temozolomide in preclinical glioblastoma using source analysis. NMR Biomed. 
2016;29(6):732-743. 
30.  Ferrer-Font L, Villamañan L, Arias-Ramos N, et al. Targeting Protein Kinase CK2: Evaluating CX-
4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals. 
2017;10(4):24. 
31.  Ferrer-Font L, Arias-Ramos N, Lope-Piedrafita S, et al. Metronomic treatment in 
immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and 
temozolomide. NMR Biomed. 2017;30(9):1-12. 
32.  Ciezka M, Acosta M, Herranz C, et al. Development of a transplantable glioma tumour model 
from genetically engineered mice: MRI/MRS/MRSI characterisation. J Neurooncol. 
2016;129(1):67-76. 
33.  Karman J, Ling C, Sandor M, Fabry Z. Initiation of Immune Responses in Brain Is Promoted by 
Local Dendritic Cells. J Immunol. 2004;173(4):2353-2361. 
34.  Kim T-G, Kim C-H, Park J-S, et al. Immunological Factors Relating to the Antitumor Effect of 
Temozolomide Chemoimmunotherapy in a Murine Glioma Model. Clin Vaccine Immunol. 
2010;17(1):143-153. 
35.  Curtin JF, Liu N, Candolfi M, et al. HMGB1 Mediates Endogenous TLR2 Activation and Brain 
Tumor Regression. Weil R, ed. PLoS Med. 2009;6(1):e1000010. 
36.  Roesch S, Rapp C, Dettling S, Herold-Mende C. When Immune Cells Turn Bad—Tumor-
Associated Microglia/Macrophages in Glioma. Int J Mol Sci. 2018;19(2):436. 
37.  Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-674. 
38.  Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A 
potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. 
39.  Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of Established Tumors by CD8+ T Cell 
Adoptive Immunotherapy. Immunity. 2000;13(2):265-276. 




immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci. 2018;115(6):E1239-
E1248. 
41.  Wu J, Jordan M, Waxman DJ. Metronomic cyclophosphamide activation of anti-tumor immunity: 
tumor model, mouse host, and drug schedule dependence of gene responses and their 
upstream regulators. BMC Cancer. 2016;16(1):623. 
42.  Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide Synergizes with Type I Interferons 
through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. 
Cancer Res. 2011;71(3):768-778. 
43.  Dai B, Qi N, Li J, Zhang G. Temozolomide combined with PD-1 Antibody therapy for mouse 
orthotopic glioma model. Biochem Biophys Res Commun. 2018;501(4):871-876. 
44.  Gilbert MR, Wang M, Aldape KD, et al. Dose-Dense Temozolomide for Newly Diagnosed 
Glioblastoma: A Randomized Phase III Clinical Trial. J Clin Oncol. 2013;31(32):4085-4091. 
45.  Szatmári T, Lumniczky K, Désaknai S, et al. Detailed characterization of the mouse glioma 261 
tumor model for experimental glioblastoma therapy. Cancer Sci. 2006;97(6):546-553. 
46.  Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination 






Figure 1. Experimental schedule of the 37 mice harboring a GL261 GB included in this work, 
corresponding to the contents of Table 1. 
 
Figure 2. Nosological images and graphical representation of the tumour volume evolution for the 
tumour region in the cases (A) C1263, (B) C1264 and (C) 1270. Tumour volume in mm3 (black line, 
left axis) and the percentage of green, responding pixels (TRI) obtained taking into account total 
pixels counting (green line, right axis). In the upper part of every image, chosen time points show 
the evolution of the nosological images in four rows of colour-coded grids superimposed to the 
T2w-MRI for each slice. Vertical arrows indicate days of therapy administration. In the graph 
below, green shaded columns indicate TMZ administration days. TRI cycle duration (therapy 
administration to next peak maxima) are highlighted in every image. In (A), from days 31 to 37 it 
was not possible to evaluate TRI evolution because tumour volume was below the limit for 
confident MRSI segmentation, which we called below detection threshold period (BDTP).  
 
Figure 3. Boxplot showing A) CD3+ positive cells/field (n=147) and B) % of Iba-1 positive 
immunostained cellular areas/field (n=148) in red and green areas of each MRSI grid of TMZ 
treated and control cases. Significant differences were observed for CD3+ positive cell counting (p 
= 0.0009) and for Iba-1 positive immunostained cellular areas (p = 0.0011) with unpaired 
Student’s t-test. The limits of the box represent quartiles 1 (Q1) and 3 (Q3) of the distribution, the 
central line corresponds to the median (quartile 2). The whiskers symbolize the maximum and 
minimum values in each distribution. Examples of C) CD3+ and D) Iba-1 immunostaining in 
different analyzed fields of case C971 corresponding with green (responsive) and red 
(unresponsive zones). Nosological images obtained from Grid 1 of the case C971 superimposed to 
the T2w-MRI. Both green and red zones could be distinguished within the tumour, showing a 
heterogeneous pattern of response. The red and green areas from the nosological image have 
been manually drawn over the tumour (shown in red and green lines). One representative field 
has been selected in each area (red and green circle have the same area). In the circular fields 
shown, cell count was 6 and 3 positive cells for CD3+ and 15.54% and 10.49% of positive 
immunostained cellular areas for Iba-1, for green and red areas, respectively. Arrows point to 
positive cells. Magnification (40×). 
 
Figure 4. Frozen dissected tumours from IMS-TMZ treated mice (A) WB for tumour total protein 
homogenate (80 µg) from different mice treated with IMS-TMZ (non-responding and relapsing 
tumours), n=9, compared with vehicle treated mice, n=3. PD-L1 and Tubulin proteins were 
analyzed. (B) Quantification of WB result including the non-responding, relapsing and control 
tumour samples, PD-L1 band intensity (after normalization to Tubulin) are 0.19 ± 0.02 in the non-
responding group, 0.64 ± 0.14 in the relapsing group and 0.23 ± 0.04 in the control group. ***=p 
<0.001 for Student’s t-test for the comparison among non-responding, relapsing and control 
group. 
 
Figure 5. Graphical representation of the tumour volume evolution, TRI cycles and re-challenge time 
point of cured mouse (C1276). T2w images shows that the tumour reached the maximum volume, 




caused by tumour growth was stable for one month (cured). On day 74 p.i cured mouse was re-
implanted on the other side of the brain parenchyma with GL261 cells, no tumour mass was 
detected in the cured mouse brain within 3 months (90 days post-rechallenge) after tumour cells 
re-injection.  
 
Figure 6. Hypothetic schema of the cycle for immune response against a preclinical GB tumour after 
two therapy cycles and resulting nosological images, using as example images from case C1270. 
The whole cycle is thought to last 6-7 days in mouse brain. When treated with TMZ at day 0 (A), 
tumour cells release and expose immunogenic signals which attract dendritic cells (DCs) and 
macrophages to the tumour site. Initially (day 1-2), the immune system is not especially active 
against these particular tumour cell clones and the nosological images correspond mostly to 
actively proliferating tumour, thus TRI is low (B). At days 3-4, DCs migrate to the lymph nodes and 
prime naïve CD8+ effector T cells, which start to proliferate. It is important that TMZ (or any 
antiproliferative agent) not to be administered in this period because it would impair lymphocytes 
proliferation and hamper proper immune response. TRI may start increasing between day 3-4 
(allowing for inter-subject variability) partially due to innate immune system action against tumour 
or to primed lymphocytes from a previous therapy cycle attacking the tumour again(C). At days 5-
6 of the cycle, a new wave of effector T cells arrive at the tumour site and jointly with macrophages 
efficiently attack the tumour. In this period, we may observe a TRI peak maximum and, in some 
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C1263 C1276# C1258 C1288 C1343 C1300 C1100 C1110 
C1264 C1281# C1260 C1319 C1349 C1317 C1108 C1111 
C1270 C1284# C1261 C1356  C1266 C971   
C1380 C1285# C1359 C1290    C1022   
C1383 C1286# C1360 C1292       
 C1382# C1361 C1341       
    C1342         
Number of 
animals 17 12 6 
MR data MRSI/MRI MRI MRSI/MRI 
Table 1. Table illustrating animal distribution in different groups investigated in this work. # means 
cured cases (see figure S3 for representative cases and section 2.4.1 for the “cured mice” criteria). 
Total “n” (35) is different from the n stated in section 2.2 and 3.1 (37) because 2 cases (C1345 and 
C1351) did not have full longitudinal follow-up with MRI and MRSI, but still, were followed up only 
with MRI (see section 2.4.1). 
 
 Primary tumour implantation 
wt control mice 
Tumour re-challenge 
IMS-TMZ cured mice 
Mice with growing tumour 3 0 
Mice rejecting tumour 0 8 
Tumour rejection rate 0% 100% 
Table 2. Comparison of GL261 tumour take rates between primary tumour implantation, and 
GL261 re-challenge in IMS-TMZ-cured mice. 
 
